Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: A network meta-analysis
Osteoporosis International Apr 12, 2019
Reginster JY, et al. - In this network meta-analysis (NMA), researchers estimated the relative effectiveness of abaloparatide vs other therapies to reduce the risk of fractures in women with postmenopausal osteoporosis (PMO). In all, abaloparatide exhibited the greatest treatment effect relative to placebo in the vertebral fracture (VF) network, the nonvertebral (NVF) network, and the wrist fracture network vs other treatments. Compared with other treatments, abaloparatide had the greatest estimated possibility to prevent the fractures in the following networks: 79% for VF, 70% for NVF, and 53% for wrist fracture.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
Sign up with M3 India to try daily quizzes and take part in competitionsTry M3 India / Log In
Why join our Market Research Panel?
- 10K+ Doctors participated in 40+ Indian and Global studies in 2018
- Average honorarium per study was Rs. 1,600 and total honoraria as high as Rs. 12,000 was earned by a Doctor